• Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024
  
• Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq Market Site in Times Square, New York City.

The Clinical Showcase will provide an opportunity to learn more about the upcoming Phase 3 trial of OCU400—including more specifics on study design and the broad indication for the treatment of retinitis pigmentosa, as well as a clinical study update from the ongoing Phase 1/2 trial of OCU400. A panel discussion will offer background on the genesis of modifier gene therapy and how this potential first-in-class treatment approach has evolved from the lab into the clinic.

Ocugen presenters include:

• Dr. Shankar Musunuri, Chairman, CEO & Co-founder
• Mike Shine, SVP Commercial
• Dr. Arun Upadhyay, CSO & Head of R&D

Panelists include:

• Dr. Lejla Vajzovic, Associate Professor of Ophthalmology with Tenure, Director of Duke Vitreoretinal Fellowship Program at Duke Eye Center and Duke University School of Medicine
• Dr. Byron Lam, Professor of Ophthalmology, Dr. Mark J. Daily, Endowed Chair in Ophthalmology at the University of Miami
• Dr. Neena Haider, inventor of modifier gene therapy, CEO & CSO Shifa Precision, faculty at Harvard Medical School
• OCU400 Phase 1/2 clinical trial patient who has completed 12 months of therapy

Nasdaq requires advance registration from attendees and registration can be done by contacting Tiffany Hamilton at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.